HA-1 TCR–transduced CD8⁺T cells kill leukemic cells. (A-B) HA-1–specific expression of CD107a on HA-1 TCR2–transduced CD8⁺ T cells showing degranulation after 5 hours of coculture (1:1) with a panel of (A) primary AML samples and (B) primary B-ALL samples. (C-F) CRAs showing lysis of leukemia and lymphoma targets by HA-1 TCR–transduced CD8⁺ T cells; lysis of (C) primary HA-1⁺ AML or HA-1^– AML by HA-1 TCR–transduced CD8⁺ T cells (blue bars) and HA-1–specific T-cell clone 2 (gray bars); (D) HLA-A2⁺/HA-1⁺ primary AML (AML1) at various E:T ratios; (E) B-ALL lines (1) BALL-1 and (2) RS4;11, T-ALL lines (1) MOLT4, (2) CEM, (3) RPMI-8402, and (4) HSB-2, and AML line NB-4; and (F) T-cell lymphoma (SUP-M2 HLA-A2⁺, HA-1⁺; SU-DHL-1 HLA-A2⁺ HA-1^–) cell lines. In panel E, HLA-A2^– and/or HA-1^– (wild-type [WT]) cell lines were transduced (TD) with LV encoding *HLA-A2 or **HLA-A2 and HA-1 minigene or ^&HA-1 minigene if the WT was HLA-A2^– or had a HA-1^– genotoype. An E:T ratio of 20:1 was used unless otherwise specified.